nedaplatin

01/01/2011 - "However, due to the lack of a randomized controlled study, nedaplatin-based CCRT has not been convincingly proven to be clinically effective in patients with cervical cancer. "
12/01/2009 - "Postoperative nedaplatin-based CCRT was safely performed and improved the prognosis of FIGO stage IA2-IIB cervical cancer patients displaying high-risk or intermediate-risk prognostic factors. "
01/01/2015 - "For nedaplatin based regimens, 5 clinical studies including 264 patients with advanced cervical cancer were considered eligible for inclusion. "
01/01/2015 - "Clinical studies evaluating the efficacy and safety of nedaplatin based regimens on response and safety for patients with cervical cancer were identified using a predefined search strategy. "
01/01/2011 - "In this study we evaluated whether the histoculture drug response assay (HDRA) could be used to predict chemosensitivity to nedaplatin (NDP) in cervical cancer. "

02/01/2000 - "The observations suggested that 254-S, which has little or no side effects including nephrotoxicity, can become the standard remedy for esophageal cancer instead of CDDP in future."
02/01/2017 - "In the clinical setting for esophageal cancer, regimens that include nedaplatin might need to be treated as HEC."
10/01/2002 - "[Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer]."
02/01/1999 - "A 60-year-old male with type 2 advanced esophageal cancer, which was located in the upper part of the esophagus and had invaded adjacent organs, was treated with nedaplatin 150 mg/body (100 mg/m2) given intravenously every 4 weeks from January 6, 1991. "
01/01/2020 - "[A Case of Advanced Esophageal Cancer Treated with Nedaplatin in a Patient Undergoing Maintenance Hemodialysis]."

12/01/2006 - "This study was to evaluate the efficacy of home-produced Nedaplatin in China on esophageal carcinoma, and observe its toxicity. "
12/01/2017 - "Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results."
01/01/2007 - "This phase I clinical trial for cervical carcinoma had three objectives: to evaluate the toxicity of a concurrent chemoradiation regimen featuring weekly nedaplatin; to determine the recommended dose of nedaplatin for a phase II concurrent chemoradiation trial; and to evaluate the formula for predicting area under the curve data for nedaplatin through pharmacokinetic studies. "
12/01/2006 - "Clinical researches in overseas showed that Nedaplatin is an anticancer drug with broad spectrum and high efficiency, especially in treating esophageal carcinoma. "
12/01/2006 - "[Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma]."

01/01/2011 - "In the current study, the sensitivity of cervical tumors to nedaplatin was predicted by the HDRA."
05/01/1992 - "A phase II study of 254-S was conducted in 134 patients with gynecological malignancies by the gynecology section of the 254-S cooperative study group. "
01/01/2014 - "Although she received 5 courses of nedaplatin, enlargement of the tumor was noticed. "
10/01/2010 - "Especially, nedaplatin has never been described to introduce secondary neoplasms. "
07/01/2007 - "To date, a total of 6 courses of CDDP and 6 courses of nedaplatin (CDGP) have been done, and the remaining pulmonary tumors have been dormant. "

12/01/2009 - "A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer."
12/01/2002 - "The aim of this study was to observe the efficacy and the side effects of nedaplatin in treatment of non-small cell lung cancer (NSCLC). "
05/01/2015 - "Nedaplatin (NDP) has been extensively used to treat patients with non-small cell lung cancer (NSCLC) in the last decade. "
04/01/2007 - "Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma."
12/01/2002 - "[Phase II clinical trial of nedaplatin in advanced non-small cell lung cancer]."